Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Mersana Therapeutics Inc (MRSN)

Mersana Therapeutics Inc (MRSN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 57,941
  • Shares Outstanding, K 124,631
  • Annual Sales, $ 40,500 K
  • Annual Income, $ -69,190 K
  • EBIT $ -73 M
  • EBITDA $ -76 M
  • 60-Month Beta 1.67
  • Price/Sales 1.38
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.56
  • Most Recent Earnings $-0.11 on 03/03/25
  • Next Earnings Date 05/08/25
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 536.29% ( -40.20%)
  • Historical Volatility 102.76%
  • IV Percentile 98%
  • IV Rank 77.41%
  • IV High 688.01% on 03/04/25
  • IV Low 16.36% on 09/09/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 22
  • Volume Avg (30-Day) 153
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 4,412
  • Open Int (30-Day) 5,328

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.20
  • Number of Estimates 4
  • High Estimate -0.17
  • Low Estimate -0.25
  • Prior Year -0.16
  • Growth Rate Est. (year over year) -25.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4462 +4.19%
on 03/13/25
0.6200 -25.02%
on 02/18/25
-0.1171 (-20.12%)
since 02/14/25
3-Month
0.4462 +4.19%
on 03/13/25
2.2400 -79.25%
on 12/16/24
-1.6851 (-78.38%)
since 12/13/24
52-Week
0.4462 +4.19%
on 03/13/25
5.1500 -90.97%
on 03/15/24
-4.5401 (-90.71%)
since 03/14/24

Most Recent Stories

More News
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results

MRSN : 0.4649 (+3.75%)
Mersana Therapeutics to Present at Upcoming Investor Conferences

MRSN : 0.4649 (+3.75%)
Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025

MRSN : 0.4649 (+3.75%)
Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MRSN : 0.4649 (+3.75%)
Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

MRSN : 0.4649 (+3.75%)
Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

MRSN : 0.4649 (+3.75%)
Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer

MRSN : 0.4649 (+3.75%)
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results

MRSN : 0.4649 (+3.75%)
Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024

MRSN : 0.4649 (+3.75%)
1 'Strong Buy' Russell 2000 Stock With 188% Upside Potential

As a part of the annual Russell Index reconstitution, this ‘Strong Buy’-rated penny stock is one of the new entrants to the Russell 2000 Index.

ADCT : 1.8500 (+4.52%)
$SPX : 5,638.94 (+2.13%)
MRSN : 0.4649 (+3.75%)

Business Summary

Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States.

See More

Key Turning Points

3rd Resistance Point 0.5090
2nd Resistance Point 0.4944
1st Resistance Point 0.4796
Last Price 0.4649
1st Support Level 0.4502
2nd Support Level 0.4356
3rd Support Level 0.4208

See More

52-Week High 5.1500
Fibonacci 61.8% 3.3531
Fibonacci 50% 2.7981
Fibonacci 38.2% 2.2431
Last Price 0.4649
52-Week Low 0.4462

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar